Equity Profile

CORT

Corcept Therapeutics Incorporated

Health CarePharmaceuticals$7.5B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Corcept Therapeutics Incorporated is a pharmaceutical company that focuses on developing and commercializing drugs for the treatment of cancer and other serious disorders. With a market cap of $7 billion, the company plays a significant role in the healthcare sector, particularly in addressing unmet medical needs through innovative therapies.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and expand its market presence, crucial for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CORT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.94%

Avg Stock Reaction

-0.00%

Last Quarter Recap

In Q1-2026, Corcept reported an EPS of -$0.30, matching analyst expectations but showing a slight negative surprise. The stock experienced a minor decline of 0.15% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Corcept's upcoming earnings are uncertain, especially given the mixed results in previous quarters. Investors are keen to see if the company can improve its financial performance.

Bull Case

If Corcept can demonstrate strong revenue growth and improved profitability, it could signal a positive turnaround, boosting investor confidence and stock price.

Bear Case

Conversely, if the company fails to meet expectations again, it may raise concerns about its long-term viability and lead to further declines in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for the upcoming quarter?

Revenue growth is critical for assessing the company's performance and potential for recovery, especially after recent mixed results.

Will there be any updates on new drug developments or clinical trials?

Updates on drug development can significantly impact investor sentiment and the company's future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for revenue growth due to recent product launches that have not yet been fully reflected in analyst models.

Supporting Evidence

Options are pricing a 20.58% move, suggesting significant expectations for volatility that may not align with historical performance.

The company's recent drug developments could lead to increased sales, which analysts might not be fully accounting for.

Key Risk

If revenue growth exceeds 15%, it could challenge the current cautious consensus and lead to a positive re-evaluation of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it follows a series of mixed results, and investors are looking for clear signs of improvement.

Bull Confirmed If

A revenue growth rate of 15% or higher would confirm the bull case and indicate strong market demand for Corcept's products.

Bear Confirmed If

A revenue decline or stagnation would confirm the bear case and raise concerns about the company's future viability.

Pre-Earnings Positioning

Options Market

Implied Move

±20.58%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant move of over 20%, indicating heightened volatility expectations around the earnings report.

Options are pricing ±20.6% while CORT has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

58.0%

Calls (72K)P/C Ratio: 1.21Puts (21K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corcept beats expectations, history suggests the stock could rise by around 0.61% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors digest the details.

Miss

If the company misses expectations, history suggests a potential decline of approximately 0.61%, leading to increased scrutiny of its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug approvals or clinical trial results.
2Details on revenue growth and sales performance in key markets.
3Management's outlook on future product launches.
4Comments on competitive pressures in the pharmaceutical sector.
5Insights into cost management and operational efficiencies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

KRCAMC

Kilroy Realty Corporation

PreviewView

Jul27

PIIAMC

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and expand its market presence, crucial for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CORT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.94%

Avg Stock Reaction

-0.00%

Last Quarter Recap

In Q1-2026, Corcept reported an EPS of -$0.30, matching analyst expectations but showing a slight negative surprise. The stock experienced a minor decline of 0.15% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Corcept can demonstrate strong revenue growth and improved profitability, it could signal a positive turnaround, boosting investor confidence and stock price.

Bear Case

Conversely, if the company fails to meet expectations again, it may raise concerns about its long-term viability and lead to further declines in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for the upcoming quarter?

Revenue growth is critical for assessing the company's performance and potential for recovery, especially after recent mixed results.

Will there be any updates on new drug developments or clinical trials?

Updates on drug development can significantly impact investor sentiment and the company's future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for revenue growth due to recent product launches that have not yet been fully reflected in analyst models.

Supporting Evidence

Options are pricing a 20.58% move, suggesting significant expectations for volatility that may not align with historical performance.

The company's recent drug developments could lead to increased sales, which analysts might not be fully accounting for.

Key Risk

If revenue growth exceeds 15%, it could challenge the current cautious consensus and lead to a positive re-evaluation of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it follows a series of mixed results, and investors are looking for clear signs of improvement.

Bull Confirmed If

A revenue growth rate of 15% or higher would confirm the bull case and indicate strong market demand for Corcept's products.

Bear Confirmed If

A revenue decline or stagnation would confirm the bear case and raise concerns about the company's future viability.

Pre-Earnings Positioning

Options Market

Implied Move

±20.58%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant move of over 20%, indicating heightened volatility expectations around the earnings report.

Options are pricing ±20.6% while CORT has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

58.0%

Calls (72K)P/C Ratio: 1.21Puts (21K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corcept beats expectations, history suggests the stock could rise by around 0.61% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors digest the details.

Miss

If the company misses expectations, history suggests a potential decline of approximately 0.61%, leading to increased scrutiny of its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug approvals or clinical trial results.
2Details on revenue growth and sales performance in key markets.
3Management's outlook on future product launches.
4Comments on competitive pressures in the pharmaceutical sector.
5Insights into cost management and operational efficiencies.